Antagonism of a PCP drug discrimination by hallucinogens and related drugs

Neuropsychopharmacology

Volumn 22, Issue 6, 2000, Pages 618-625

  West, William B ^a   Lon, Alice ^a   Pechersky, Kara ^a   Chachich, Mark E ^a   Appel, James B ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Behavior; Dopamine; LSD; NMDA; Schizophrenia; Serotonin

Indexed keywords

2,5 DIMETHOXY 4 METHYLAMPHETAMINE; LISURIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N,N DIMETHYLTRYPTAMINE; PHENCYCLIDINE; PSYCHEDELIC AGENT; RITANSERIN; SEROTONIN 2A RECEPTOR; SPIPERONE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DISCRIMINATION; INTERNEURON; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; SCHIZOPHRENIA;

2,5-DIMETHOXY-4-METHYLAMPHETAMINE; ANIMALS; BRAIN; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; LISURIDE; LYSERGIC ACID DIETHYLAMIDE; MALE; N,N-DIMETHYLTRYPTAMINE; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; RITANSERIN; SPIPERONE; TIME FACTORS;

EID: 0034007304     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00163-3     Document Type: Article

References (31)

1. Appel JB, White FJ, Holohean AM (1982): Analyzing mechanising) of hallucinogenic drug action with drug discrimination procedures. Neurosci Biobehav Rev 6:529-536
2. Balster RL (1991): Discriminative stimulus properties of phencyclidine and other NMDA antagonists. NIDA Res Monogr 116:163-180
3. Branchek T, Adham N, Macchi M, Kao HT, Hartig PR (1990): [3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor. Mol Pharmacol 38:604-609
4. Burris KD, Breeding M, Sanders-Bush E (1991): (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist. J Pharmacol Exp Ther 258:891-896
5. Cunningham KA, Appel JB (1987): Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD). Psychopharmacology (Berl) 91:67-73
6. Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M (1998): Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacology (Berl.) 136:409-il4
7. Farber NB, Hanslick J, Kirby C, McWilliams L, Olney JW (1998): Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology 18:57-62
8. Fiorella D, Palumbo PA, Rabin RA, Winter JC (1995a): The time-dependent stimulus effects of R(-)-2,5-dimethoxy4- methamphetamine (DOM): Implications for druginduced stimulus control as a method for the study of hallucinogenic agents. Psychopharmacology (Berl) 119: 239-245
9. Fiorella D, Rabin RA, Winter JC (1995b): Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. II. Reassessment of LSD false positives. Psychopharmacology (Berl) 121:357-363
10. Fix AS, Wozniak DF, Truex LL, McEwen M, Miller JP, Olney JW (1995): Quantitative analysis of factors influencing neuronal necrosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex. Brain Res 696:194-204
11. Glennon RA, Raghupathi R, Bartyzel P, Teitler M, Leonhardt S (1992): Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: Evidence for a lack of selectivity. J Med Chem 35:734-740
12. Glennon RA, Rosecrans JA, Young R (1983): Drug-induced discrimination: A description of the paradigm and a review of its specific application to the study of hallucinogenic agents. Med Res Rev 3:289-340
13. Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D, LaRue L (1995): Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischémie stroke. Results of a phase Ha randomized trial. Stroke 26:602-605
14. Javitt DC, Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308
15. Koek W (1999): N-methyl-D-aspartate antagonists and drug discrimination. Pharmacol Biochem Behav 64(2):275-281
16. Koek W, Woods J (1988): Correlations between phencyclidine like-activity and N-methyl-d-aspartate antagonism: Behavioral evidence. In Domino E, Kamenka J (eds), Sigma and phencyclidine-like compounds as molecular probes in biology. Ann Arbor, NPP Books, pp 357-372
17. Koek W, Woods JH, Colpaert FC (1990): N-methyl-D-aspartate antagonism and phencyclidine-like activity: A drug discrimination analysis. J Pharmacol Exp Ther 253:1017-1025
18. Krebs-Thomson K, Paulus MP, Geyer MA (1998): Effects of hallucinogens on locomotor and investigatory activity and patterns: Influence of 5-HT2A and 5-HT2C receptors. Neuropsychopharmacology 18:339-351
19. Kristensen JD, Svensson B, Gordh T Jr (1992): The NMDAreceptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans. Pain 51:249-253
20. Lodge D, Anis NA (1982): Effects of phencyclidine on excitatory amino acid activation of spinal interneurones in the cat. Eur J Pharmacol 77:203-204
21. Luby E, Gottlieb J, Cohen B, Rosenbaum G, Domino E (1962): Model psychosis and schizophrenia. Am J Psychiatry 119:61-67
22. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelly R (1959): Study of a new schizophrenic-like drug: Semyl. Arch Neurol Psychiatry 81:363-369
23. Marek GJ, Aghajanian GK (1996): LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. J Pharmacol Exp Ther 278:1373-1382
24. Olney JW, Farber NB (1995a): Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:9981007
25. Olney JW, Farber NB (1995b): NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13:335-345
26. Olney JW, Labruyere J, Price MT (1989): Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244:1360-1362
27. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA (1991): NMDA antagonist neurotoxicity: Mechanism and prevention. Science 254:1515-1518
28. Sheldon PW, Aghajanian GK (1990): Serotonin (5-HT) induces IPSPs in pyramidal layer cells of rat piriform cortex: Evidence for the involvement of a 5-HT2-activated interneuron. Brain Res 506:62-69
29. Smith RL, Canton H, Barrett RJ, Sanders-Bush E (1998): Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5- HT2C receptors. Pharmacol Biochem Behav 61:323-330
30. Tallarida R, Murray R (1987): Manual of pharmacological calculations with computers. New York, Springer-Verlag
31. White FJ, Appel JB (1982): Lysergic acid diethylamide (LSD) and lisuride: Differentiation of their neuropharmacological actions. Science 216:535-537